Danica Pension Livsforsikringsaktieselskab Makes New Investment in Boston Scientific Corporation $BSX

Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 620,861 shares of the medical equipment provider’s stock, valued at approximately $26,498,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Kelleher Financial Advisors purchased a new position in shares of Boston Scientific in the 2nd quarter worth $25,000. FWL Investment Management LLC purchased a new stake in Boston Scientific during the second quarter valued at about $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific during the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific in the 4th quarter worth about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of Boston Scientific in the 1st quarter worth about $28,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

BSX stock opened at $50.51 on Wednesday. The firm has a market cap of $73.20 billion, a P/E ratio of 20.45, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The stock has a 50-day simple moving average of $46.15 and a 200-day simple moving average of $58.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has initiated a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Boston Scientific

In other news, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research reports. Truist Financial decreased their target price on Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. TD Cowen reduced their price target on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Bank of America decreased their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Finally, Stifel Nicolaus set a $60.00 price objective on shares of Boston Scientific in a research report on Wednesday, July 29th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.